Regulatory agencies of different European countries and the United States have 
been critically examining the possible link between suicidality and 
antidepressant use in children and adults, which has resulted in an FDA 
directive to the manufacturers of all antidepressant medications to add a 'black 
box' warning. 'Black box' warning describes the increased risk of suicidality in 
persons who take antidepressants. Because the news media's coverage of the 
antidepressant-suicide controversy has increased dramatically in the last few 
years, serious concerns need to be performed. In this review, the possible 
risk-benefit ratio has been estimated according to the use of selective 
serotonin reuptake inhibitors (SSRIs) antidepressants due to relevant 
psychobiological, clinical and epidemiologic data.